Document is current
Any future updates will be listed below
-
Authors
Godfrey, Caroline
Desviat, Lourdes R
Smedsrød, Bård
Piétri‐Rouxel, France
Denti, Michela A
Disterer, Petra
Lorain, Stéphanie
Nogales‐Gadea, Gisela
Sardone, Valentina
Anwar, Rayan
EL Andaloussi, Samir
Lehto, Taavi
Khoo, Bernard
Brolin, Camilla
van Roon‐Mom, Willeke MC
Goyenvalle, Aurélie
Aartsma‐Rus, Annemieke
Arechavala‐Gomeza, Virginia https://orcid.org/0000-0001-7703-3255
-
Funding
Funding for this research was provided by:
Ministerio de Economia y Competitividad (SAF2013‐43005‐R)
European Cooperation in Science and Technology (BM1207)
Duchenne Parent Project
Instituto de Salud Carlos III (CP14/00032)
Instituto de Salud Carlos III (CP12/03057)
Fondo de investigaciones sanitarias (PI15/01756)
European Regional Development Fund (SAF2013‐43005‐R)
European Commission (618003)
European Commission (FP7‐PEOPLE‐2013‐CIG)
Seventh Framework Programme (CP12/03057)
Seventh Framework Programme (CP14/00032)
Seventh Framework Programme (PI15/01756)
Seventh Framework Programme (2012‐305121)
Seventh Framework Programme (305370)
Sarepta Therapeutics
Ministry of Economy, Israel
Svenska Forskningsrådet Formas (VR‐Med and EuroNanoMedII)
Swedish Society of Medical Research
Eesti Teadusagentuur (PUTJD71)
Wellcome Trust
Swedish Institute
Medical Research Council (G0802469)
British Heart Foundation
Danish Council for Independent Research
Netherlands Organisation for Health Research and Development (40‐41900‐98‐018)
Hersenstichting (BG2013‐03)
AFM‐Téléthon (20055)
Institut National de la Santé et de la Recherche Médicale
Agence Nationale de la Recherche (handiMedEx)
Fundación Ramón Areces
Prinses Beatrix Spierfonds (W.OR 13‐6)
E.Rare (Splice‐EB)
Tromsø Research Foundation
Fondazione Telethon (GGP08244)
Italian Ministry of Health (GR‐2008‐1136933)
Italian Ministry of Health (RF‐2011‐02347694)
Ministry of Science, Technology and Space, Israel
- License Information
-
More Information
Article History
Received: 14 October 2016
Revised: 15 December 2016
Accepted: 13 February 2017
First Online: 13 March 2017
Conflict of interest
: B.S. is the founder and CEO of D'Liver, NO. V.S. is supported by funding provided by Sarepta Therapeutics, US. W.v.R.M. is the main inventor on two published patent applications WO2012/018257 and WO2015/053624 regarding exon skipping approaches for neurodegenerative diseases and co‐inventor on one provisional patent US 62/315,512. A.A.R. reports being employed by LUMC, which has patents on exon skipping technology. As co‐inventor on some of these patents she stands to gain financially from potential royalties and she is also on the SAB of Philae Pharmaceuticals and ProQR and has been ad hoc consultant for Summit PLC, BioClinica, GLG consulting, Deerfield, Global Guidepoint, PTC Therapeutics, BioMarin and BMS and has presented at satellite symposia organized by PTC and BioMarin. Remuneration for SAB and consulting activities and speaker honoraria went to her employer. All other authors declare no conflicts of interest.
